Page last updated: 2024-11-01

omeprazole and Obesity

omeprazole has been researched along with Obesity in 11 studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
" Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months)."9.51Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics. ( Bandrés, F; Castrillón, EV; Chicharro, LM; López-Picado, A; Moreno Lopera, C; Paterna, ABR; Portolés-Pérez, A; Rubio, MA; Sánchez Pernaute, A; Torres García, AJ, 2022)
"The effect of different administration routes of omeprazole remains unclear on the recovery in patients with obesity after laparoscopic sleeve gastrectomy (LSG)."9.41Comparison of Outcomes in Patients with Obesity Between Two Administration Routes of Omeprazole After Laparoscopic Sleeve Gastrectomy: An Open-Label Randomized Clinical Trial. ( Gao, Y; Huang, W; Huo, Y; Lu, Y; Tan, Q; Zhang, P, 2021)
" Omeprazole improved the anorectic and body weight-lowering effects and reversed the inhibitory effect of exendin-4 on gastrin levels after repeated dose treatment."7.79Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*. ( Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V, 2013)
" Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months)."5.51Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics. ( Bandrés, F; Castrillón, EV; Chicharro, LM; López-Picado, A; Moreno Lopera, C; Paterna, ABR; Portolés-Pérez, A; Rubio, MA; Sánchez Pernaute, A; Torres García, AJ, 2022)
"To investigate whether overweight/obesity (BMI≥25 kg/m(2)) affects rabeprazole clinical efficacy versus omeprazole in patients with erosive esophagitis (EE)."5.15Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. ( Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J, 2011)
" Omeprazole improved the anorectic and body weight-lowering effects and reversed the inhibitory effect of exendin-4 on gastrin levels after repeated dose treatment."3.79Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*. ( Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V, 2013)
"Obesity is associated with a risk of gastroesophageal reflux disease."2.79Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. ( Belhocine, K; Bruley des Varannes, S; Flet, L; Touchefeu, Y; Vavasseur, F; Volteau, C, 2014)
" Omeprazole is the most common option utilized for acid-related disorders ; however, the pharmacokinetic (PK) and dosing recommendations for the obese patient population are lacking."1.72Population pharmacokinetics of omeprazole in obese and normal-weight adults. ( Chen, K; Deng, C; Ding, J; Lin, Y; Luo, P; Pei, Q; Yang, G; Zhu, L; Zhu, S, 2022)
"Gastroesophageal reflux is a well-recognized complication of obesity."1.35Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND. ( Chang, CG; Perez, E, 2009)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19901 (9.09)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's5 (45.45)24.3611
2020's3 (27.27)2.80

Authors

AuthorsStudies
Portolés-Pérez, A1
Paterna, ABR1
Sánchez Pernaute, A1
Torres García, AJ1
Moreno Lopera, C1
Chicharro, LM1
Bandrés, F1
López-Picado, A1
Rubio, MA1
Castrillón, EV1
Chen, K1
Luo, P1
Yang, G1
Zhu, S1
Deng, C1
Ding, J1
Lin, Y1
Zhu, L1
Pei, Q1
Tan, Q1
Gao, Y1
Zhang, P1
Huo, Y1
Lu, Y1
Huang, W1
Belhocine, K1
Vavasseur, F1
Volteau, C1
Flet, L1
Touchefeu, Y1
Bruley des Varannes, S1
Cohen, H1
Tomasso, G1
Luisa Cafferata, M1
Zapata, C1
Sharma, P2
Armstrong, D1
Moraes-Filho, JP1
Blasco, C1
Corti, R1
Estape, G1
Leite Luna, L1
Ortuño, R1
Sakai, P1
Salis, G1
Taullard, D1
Trakal, E1
Valdovinos, M1
Vergara, M1
Gónzalez, O1
Chang, CG1
Perez, E1
Pace, F1
Coudsy, B1
DeLemos, B1
Sun, Y1
Xiang, J1
LoCoco, J1
Casalini, S1
Li, H1
Pelosini, I1
Scarpignato, C1
Blackler, R1
Syer, S1
Bolla, M1
Ongini, E1
Wallace, JL1
Patel, V1
Joharapurkar, A1
Gandhi, T1
Patel, K1
Dhanesha, N1
Kshirsagar, S1
Dhote, V1
Detroja, J1
Bahekar, R1
Jain, M1
Ashley, SW1
Cheung, LY1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01136317]Phase 20 participants Interventional2010-04-30Completed
Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus[NCT02464930]220 participants (Anticipated)Observational2015-04-30Recruiting
Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus[NCT01572987]12 participants (Actual)Interventional2011-09-30Terminated (stopped due to Recruitment goals not being met)
Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy for Screening of Barrett's Esophagus: A Prospective Tandem Study[NCT03167970]21 participants (Actual)Observational2017-05-03Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for omeprazole and Obesity

ArticleYear
Latin american consensus on gastroesophageal reflux disease: an update on therapy.
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:2

    Topics: Alginates; Antacids; Anti-Ulcer Agents; Cohort Studies; Consensus; Dose-Response Relationship, Drug;

2010
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009
Clinical practice. Barrett's esophagus.
    The New England journal of medicine, 2009, Dec-24, Volume: 361, Issue:26

    Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E

2009

Trials

4 trials available for omeprazole and Obesity

ArticleYear
Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics.
    Obesity facts, 2022, Volume: 15, Issue:2

    Topics: Body Mass Index; Body Weight; Female; Gastric Bypass; Humans; Male; Obesity; Obesity, Morbid; Omepra

2022
Comparison of Outcomes in Patients with Obesity Between Two Administration Routes of Omeprazole After Laparoscopic Sleeve Gastrectomy: An Open-Label Randomized Clinical Trial.
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Gastrectomy; Humans; Infusions, Intravenous; Injections, Intravenous; Laparoscopy; Obesity; Omeprazo

2021
Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.
    BMC gastroenterology, 2014, Jul-15, Volume: 14

    Topics: Adult; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Io

2014
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, P

2011

Other Studies

5 other studies available for omeprazole and Obesity

ArticleYear
Population pharmacokinetics of omeprazole in obese and normal-weight adults.
    Expert review of clinical pharmacology, 2022, Volume: 15, Issue:4

    Topics: Adult; Cytochrome P-450 CYP2C19; Genotype; Humans; Obesity; Omeprazole; Proton Pump Inhibitors

2022
Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND.
    Obesity surgery, 2009, Volume: 19, Issue:11

    Topics: Anti-Ulcer Agents; Barrett Esophagus; Esophagitis; Esophagoscopy; Gastrectomy; Gastric Bypass; Gastr

2009
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi

2012
Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
    Journal of diabetes, 2013, Volume: 5, Issue:2

    Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exe

2013
The SSAT-AGA (Society for Surgery of the Alimentary Tract-American Gastroenterological Association). New Orleans, May 20-23, 1984.
    Surgical gastroenterology, 1984, Volume: 3, Issue:2

    Topics: Animals; Benzimidazoles; Colitis, Ulcerative; Colon; Common Bile Duct; Crohn Disease; Digestive Syst

1984